Biotechnology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Biopharmaceuticals, Bio-IT, Bio- Industrial, Bio-Agriculture), By End User (Biotechnology & Pharmaceutical Companies, Research Institutes & Laboratories, Academic Institutions, Others), By Region and Competition, 2020-2030F
The Global Biotechnology Market, valued at USD 1.45 Trillion in 2024, is projected to experience a CAGR of 12.85% to reach USD 2.99 Trillion by 2030. Biotechnology encompasses the application of biological systems and processes to develop products and technologies that advance human health, agriculture, and industrial processes. Key drivers supporting the market's expansion include the increasing global prevalence of chronic and infectious diseases, necessitating advanced therapeutic and diagnostic solutions, alongside continuous advancements in genomics, molecular biology, and genetic engineering. The growing demand for personalized medicine also provides substantial impetus for market development.
Key Market Drivers
The biotechnology market is significantly propelled by breakthroughs in genetic engineering and gene editing technologies. These advancements, exemplified by tools such as CRISPR, enable precise modifications to genetic material, offering unprecedented potential for treating diseases at their root cause. This has led to a rapid expansion in therapeutic development, moving beyond conventional small molecules and biologics. This momentum is clearly reflected in regulatory milestones, as according to RegMedNet, May 2025, FDA-Approved Cell and Gene Therapies, the US Food and Drug Administration approved nine cell and gene therapy products in 2024, signaling a robust pipeline translating into tangible patient solutions.
Key Market Challenges
The substantial capital investment necessitated by extensive research and development activities presents a considerable impediment to the growth of the global biotechnology market. Developing innovative biological systems and processes demands significant, long-term financial commitments, often over many years before a product can reach commercialization. This inherent financial burden acts as a barrier, particularly for smaller biotechnology firms, limiting their capacity to pursue novel therapeutic and diagnostic solutions. For larger entities, the high costs can lead to a more conservative investment strategy, focusing resources on fewer, higher-probability projects, which can slow the overall pace of innovation and restrict the diversity of product pipelines across the industry.
Key Market Trends
The adoption of artificial intelligence in drug discovery and development is revolutionizing the pharmaceutical pipeline by enhancing the speed and efficiency of identifying drug candidates, optimizing lead compounds, and predicting clinical outcomes. This technology reduces the time and cost traditionally associated with bringing new therapies to market. For instance, according to the Massachusetts Biotechnology Council, Massachusetts-headquartered biopharma companies collectively received $7.89 billion in venture capital funding in 2024, reflecting substantial investment in innovation that includes AI-driven methodologies. Further illustrating this trend, Bexorg, Inc. announced the completion of a $23 million Series A financing in October 2025, specifically aimed at advancing its integrated AI and whole-human brain platform for central nervous system drug discovery and development.
Key Market Players
In this report, the Global Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Biotechnology Market.
Available Customizations:
Global Biotechnology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
The biotechnology market is significantly propelled by breakthroughs in genetic engineering and gene editing technologies. These advancements, exemplified by tools such as CRISPR, enable precise modifications to genetic material, offering unprecedented potential for treating diseases at their root cause. This has led to a rapid expansion in therapeutic development, moving beyond conventional small molecules and biologics. This momentum is clearly reflected in regulatory milestones, as according to RegMedNet, May 2025, FDA-Approved Cell and Gene Therapies, the US Food and Drug Administration approved nine cell and gene therapy products in 2024, signaling a robust pipeline translating into tangible patient solutions.
Key Market Challenges
The substantial capital investment necessitated by extensive research and development activities presents a considerable impediment to the growth of the global biotechnology market. Developing innovative biological systems and processes demands significant, long-term financial commitments, often over many years before a product can reach commercialization. This inherent financial burden acts as a barrier, particularly for smaller biotechnology firms, limiting their capacity to pursue novel therapeutic and diagnostic solutions. For larger entities, the high costs can lead to a more conservative investment strategy, focusing resources on fewer, higher-probability projects, which can slow the overall pace of innovation and restrict the diversity of product pipelines across the industry.
Key Market Trends
The adoption of artificial intelligence in drug discovery and development is revolutionizing the pharmaceutical pipeline by enhancing the speed and efficiency of identifying drug candidates, optimizing lead compounds, and predicting clinical outcomes. This technology reduces the time and cost traditionally associated with bringing new therapies to market. For instance, according to the Massachusetts Biotechnology Council, Massachusetts-headquartered biopharma companies collectively received $7.89 billion in venture capital funding in 2024, reflecting substantial investment in innovation that includes AI-driven methodologies. Further illustrating this trend, Bexorg, Inc. announced the completion of a $23 million Series A financing in October 2025, specifically aimed at advancing its integrated AI and whole-human brain platform for central nervous system drug discovery and development.
Key Market Players
- Novo Nordisk A/S
- Regeneron Pharmaceuticals Inc.
- Amgen, Inc.
- CSL Limited
- Gilead Sciences, Inc.
- Celgene Corporation
- Biogen Inc.
- Vertex Pharmaceuticals, Inc.
- Seagen Inc.
- Genmab A/S
In this report, the Global Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Biotechnology Market, By Application:
- Biopharmaceuticals
- Bio-IT
- Bio- Industrial
- Bio-Agriculture
- Biotechnology Market, By End User:
- Biotechnology & Pharmaceutical Companies
- Research Institutes & Laboratories
- Academic Institutions
- Others
- Biotechnology Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies presents in the Global Biotechnology Market.
Available Customizations:
Global Biotechnology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL BIOTECHNOLOGY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Application (Biopharmaceuticals, Bio-IT, Bio- Industrial, Bio-Agriculture)
5.2.2. By End User (Biotechnology & Pharmaceutical Companies, Research Institutes & Laboratories, Academic Institutions, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. NORTH AMERICA BIOTECHNOLOGY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Application
6.2.2. By End User
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Biotechnology Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Application
6.3.1.2.2. By End User
6.3.2. Canada Biotechnology Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Application
6.3.2.2.2. By End User
6.3.3. Mexico Biotechnology Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Application
6.3.3.2.2. By End User
7. EUROPE BIOTECHNOLOGY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Application
7.2.2. By End User
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Biotechnology Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Application
7.3.1.2.2. By End User
7.3.2. France Biotechnology Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Application
7.3.2.2.2. By End User
7.3.3. United Kingdom Biotechnology Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Application
7.3.3.2.2. By End User
7.3.4. Italy Biotechnology Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Application
7.3.4.2.2. By End User
7.3.5. Spain Biotechnology Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Application
7.3.5.2.2. By End User
8. ASIA PACIFIC BIOTECHNOLOGY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Application
8.2.2. By End User
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Biotechnology Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Application
8.3.1.2.2. By End User
8.3.2. India Biotechnology Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Application
8.3.2.2.2. By End User
8.3.3. Japan Biotechnology Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Application
8.3.3.2.2. By End User
8.3.4. South Korea Biotechnology Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Application
8.3.4.2.2. By End User
8.3.5. Australia Biotechnology Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Application
8.3.5.2.2. By End User
9. MIDDLE EAST & AFRICA BIOTECHNOLOGY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Application
9.2.2. By End User
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Biotechnology Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Application
9.3.1.2.2. By End User
9.3.2. UAE Biotechnology Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Application
9.3.2.2.2. By End User
9.3.3. South Africa Biotechnology Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Application
9.3.3.2.2. By End User
10. SOUTH AMERICA BIOTECHNOLOGY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Application
10.2.2. By End User
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Biotechnology Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Application
10.3.1.2.2. By End User
10.3.2. Colombia Biotechnology Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Application
10.3.2.2.2. By End User
10.3.3. Argentina Biotechnology Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Application
10.3.3.2.2. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL BIOTECHNOLOGY MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Novo Nordisk A/S
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Regeneron Pharmaceuticals Inc.
15.3. Amgen, Inc.
15.4. CSL Limited
15.5. Gilead Sciences, Inc.
15.6. Celgene Corporation
15.7. Biogen Inc.
15.8. Vertex Pharmaceuticals, Inc.
15.9. Seagen Inc.
15.10. Genmab A/S
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL BIOTECHNOLOGY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Application (Biopharmaceuticals, Bio-IT, Bio- Industrial, Bio-Agriculture)
5.2.2. By End User (Biotechnology & Pharmaceutical Companies, Research Institutes & Laboratories, Academic Institutions, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. NORTH AMERICA BIOTECHNOLOGY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Application
6.2.2. By End User
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Biotechnology Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Application
6.3.1.2.2. By End User
6.3.2. Canada Biotechnology Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Application
6.3.2.2.2. By End User
6.3.3. Mexico Biotechnology Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Application
6.3.3.2.2. By End User
7. EUROPE BIOTECHNOLOGY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Application
7.2.2. By End User
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Biotechnology Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Application
7.3.1.2.2. By End User
7.3.2. France Biotechnology Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Application
7.3.2.2.2. By End User
7.3.3. United Kingdom Biotechnology Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Application
7.3.3.2.2. By End User
7.3.4. Italy Biotechnology Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Application
7.3.4.2.2. By End User
7.3.5. Spain Biotechnology Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Application
7.3.5.2.2. By End User
8. ASIA PACIFIC BIOTECHNOLOGY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Application
8.2.2. By End User
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Biotechnology Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Application
8.3.1.2.2. By End User
8.3.2. India Biotechnology Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Application
8.3.2.2.2. By End User
8.3.3. Japan Biotechnology Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Application
8.3.3.2.2. By End User
8.3.4. South Korea Biotechnology Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Application
8.3.4.2.2. By End User
8.3.5. Australia Biotechnology Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Application
8.3.5.2.2. By End User
9. MIDDLE EAST & AFRICA BIOTECHNOLOGY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Application
9.2.2. By End User
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Biotechnology Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Application
9.3.1.2.2. By End User
9.3.2. UAE Biotechnology Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Application
9.3.2.2.2. By End User
9.3.3. South Africa Biotechnology Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Application
9.3.3.2.2. By End User
10. SOUTH AMERICA BIOTECHNOLOGY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Application
10.2.2. By End User
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Biotechnology Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Application
10.3.1.2.2. By End User
10.3.2. Colombia Biotechnology Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Application
10.3.2.2.2. By End User
10.3.3. Argentina Biotechnology Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Application
10.3.3.2.2. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL BIOTECHNOLOGY MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Novo Nordisk A/S
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Regeneron Pharmaceuticals Inc.
15.3. Amgen, Inc.
15.4. CSL Limited
15.5. Gilead Sciences, Inc.
15.6. Celgene Corporation
15.7. Biogen Inc.
15.8. Vertex Pharmaceuticals, Inc.
15.9. Seagen Inc.
15.10. Genmab A/S
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
